Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.